SHR-A1921 + adebrelimab

SHR-A1921 + adebrelimab is an investigational combination therapy comprising two agents: - **SHR-A1921** is an antibody-drug conjugate (ADC) under development for the treatment of various solid tumors, including platinum-resistant ovarian cancer. It delivers a cytotoxic payload to tumor cells by targeting specific antigens expressed on their surface. - **Adebrelimab** is a humanized IgG4 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1). By inhibiting PD-L1, it blocks the interaction with PD-1 on T cells, thereby enhancing anti-tumor immune responses. Adebrelimab has been approved in China for small cell lung cancer and is being investigated in other cancers. The combination aims to leverage direct tumor cell killing by the ADC and immune checkpoint blockade by the anti-PD-L1 antibody. The primary indication under investigation for this combination includes advanced non-small cell lung cancer after failure of first-line standard therapy[2].

Brand names

Ariely

Other names

HTI-1088HTI1088HTI 1088HTI-1316HTI1316HTI 1316